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70 mg/m2 on days 64 and 92, and fluorouracil 700 mg/m2 
on days 64–67 and 92–95, concurrently with radiotherapy 
(60 Gy in 30 fractions, 5 days/week). Primary endpoint of 
the phase II part was CR rate.
Results Thirty-three patients were enrolled. The completion 
rate of protocol treatment was 88 %. Thirteen patients (39.4 %) 
achieved a CR. With a median follow-up period of 41 months 
(range 24–49 months), median progression-free survival was 
12.2 months, and median survival was 26.0 months, with a 
survival rate of 40.4 % at 3 years. The most common grade 
3 or 4 toxicities were neutropenia, leukopenia, anorexia and 
dysphagia. No treatment-related death was observed.
Conclusion Induction chemotherapy with DCF followed 
by CRT is tolerable and shows promising efficacy for unre-
sectable locally advanced ESCC.
Keywords Esophageal carcinoma · Squamous cell 
carcinoma · Induction chemotherapy · Chemoradiotherapy · 
DCF
Abstract 
Purpose  Standard care for unresectable locally advanced 
esophageal squamous cell carcinoma (ESCC) is concurrent 
chemoradiotherapy, but survival remains limited. Neoadju-
vant chemotherapy with docetaxel, cisplatin and fluoroura-
cil (DCF) has demonstrated promising activity, with a path-
ological complete response (CR) of 17 % for resectable 
stage II/III ESCC. Here, we conducted a multicenter study 
to assess the efficacy and safety of induction chemotherapy 
with DCF followed by CRT in patients with unresectable 
locally advanced ESCC.
Methods Eligibility criteria included clinical T4 and/or M1 
lymph node ESCC, PS 0–1 and age 20–70 years. Treatment 
consisted of docetaxel 70 mg/m2 and cisplatin 70 mg/m2 on 
day 1, and fluorouracil 750 mg/m2 on days 1–5, repeated 
every 3 weeks for three cycles, followed by cisplatin 
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Introduction
Esophageal squamous cell carcinoma (ESCC) is a highly 
malignant disease. The high frequency of unresectable 
primary disease, distant metastases or medical unsuitabil-
ity for surgery at initial diagnosis means that 40–60 % of 
patients are not candidates for surgery, and their progno-
sis remains dismal [1]. Curative resection is not feasible 
in patients with locally advanced ESCC, particularly those 
with direct invasion of adjacent organs T4, and such cases 
have an unfavorable prognosis [2–4]. Standard care for 
unresectable locally advanced ESCC is concurrent chemo-
radiotherapy (CRT). A combination of cisplatin and fluo-
rouracil (CF) has become the standard regimen, but sur-
vival remains poor [5–7]. A previous study of CRT with 
CF plus 60 Gy of radiation in patients who had ESCC with 
T4 tumors and/or M1 lymph node metastasis (M1 LYM) 
showed a CR rate of 15–33 % and 3-year overall survival 
rate of 23–26 % [3, 8, 9].
Docetaxel has shown activity against many solid tumors 
as monotherapy and in combination with other agents. Doc-
etaxel has a different mechanism of action to CF and has 
been proved to have an additive effect with cisplatin and 
supra-additive antitumor activity with fluorouracil in vitro 
and in murine models of xenografted human tumors [10, 
11]. Two phase III trials showed survival benefits from 
induction chemotherapy with docetaxel plus cisplatin and 
fluorouracil (DCF) compared to CF in locally advanced 
head and neck squamous cell carcinoma [12, 13]. Neoad-
juvant chemotherapy with DCF demonstrated promising 
activity with a pathological CR rate of 17 % for resectable 
stage II/III ESCC [14]. Results were also promising in a 
phase II trial of DCF followed by carboplatin and radio-
therapy in locally advanced ESCC [15]. Furthermore, the 
risk of perforation of the esophageal wall related to defini-
tive CRT has been highlighted in patients with T4 disease. 
To reduce the risk of perforation, we decided to use induc-
tion chemotherapy before CRT, with the aim of decreas-
ing tumor volume before encountering severe esophagi-
tis. However, the efficacy and safety of induction DCF 
followed by CF-RT for ESCC with T4 tumors and/or M1 
lymph node metastasis (M1 LYM) has not been reported.
In this study, we aimed to assess the efficacy and safety 
of induction chemotherapy with DCF followed by CRT in 
patients with unresectable locally advanced ESCC.
Materials and methods
Eligibility criteria
Eligibility criteria were age 20–70 years; histologically 
proven squamous cell carcinoma of the esophagus; primary 
lesion located within the thoracic esophagus; no distant 
organ metastases; no esophagobronchial or esophagome-
diastinal fistulas; Eastern Cooperative Oncology Group 
(ECOG) performance status (PS) <2; adequate organ func-
tion defined by hemoglobin ≥10 g/dl, absolute neutrophil 
count ≥2×109/l, platelet count ≥100 × 109/l, total biliru-
bin ≤1.5 mg/dl and serum transaminases ≤3 × the upper 
normal limit (UNL) of the institution and creatinine clear-
ance ≥60 mL/min, PaO2 ≥70 mmHg; and tumors judged 
unresectable by computed tomography (CT) scan defined 
by (1) primary tumor invasion depth T4 and/or (2) meta-
static regional lymph node invasion to adjacent organs and/
or (3) M1 lymph node (M1 LYM). T4 was defined as a 
tumor that invades contiguous structures and M1 LYM as 
nodal metastasis beyond the regional lymph nodes, such 
as the supraclavicular or celiac lymph nodes (International 
Union Against Cancer TNM classification system, sixth 
edition). All areas of nodal disease had to be encompass-
able within the radiation field. Exclusion criteria were his-
tory of prior chemotherapy; myocardial infarction within 
the last 3 months; history of unstable angina pectoris, 
intestinal pneumonia, fibroid lung or severe emphysema; 
concurrent active malignancy; uncontrolled infection; and 
pregnancy or lactation. All patients were required to pro-
vide written informed consent before entering the study, 
which was approved by the institutional review board at 
each participating center.
Study design and treatment
The concurrent phase I part of the study was conducted in 
two cancer centers, and the subsequent phase II part was 
conducted in seven referral centers. Protocol treatment 
was defined as induction chemotherapy consisting of doc-
etaxel (DTX), cisplatin (CDDP) plus fluorouracil (5-FU) 
(DCF) followed by chemoradiotherapy concurrent with 
CDDP plus 5-FU. Induction chemotherapy consisted of a 
1-h intravenous (i.v.) administration of DTX on day 1; 2-h 
infusion of CDDP on day 1; and continuous i.v. administra-
tion of 5-FU on days 1–5. This regimen was repeated every 
3 weeks for a maximum of up to three cycles. Chemora-
diotherapy consisted of concurrent administration of CDDP 
(70 mg/m2 on days 64 and 92) plus 5-FU (700 mg/m2 on 
days 64–67 and 92–95) with radiotherapy.
Radiotherapy consisted of 60 Gy with a daily dose of 
2 Gy and was delivered with ≥6-MV X-rays. Three-dimen-
sional treatment planning with a CT stimulator was used. 
Gross tumor volume (GTV) was determined by pretreat-
ment with CT and GI endoscopy. Clinical target volume 
(CTV) included GTV with a craniocaudal margin of 3 cm 
in the primary site and a margin of 0–1 cm in lymph node 
metastases. Because target volume is always large in far-
advanced esophageal cancer, no prophylactic irradiation 
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for lymph node areas was performed. Completion of pro-
tocol treatment was defined as the end of induction DCF 
followed by concurrent CF-RT consisting of 60 Gy within 
24 weeks from the date of first administration of induction 
DCF.
Prophylactic use of granulocyte colony-stimulating fac-
tor (G-CSF) was not allowed, but ciprofloxacin was admin-
istered on days 5–15.
The phase I part was designed to determine the recom-
mended dose (RD) of induction chemotherapy. Six patients 
were treated at dose level 1 (DTX 70 mg/m2, CDDP 
70 mg/m2 and 5-FU 750 mg/m2). If three or more of the 
six patients experienced a dose-limiting toxicity (DLT), 
six additional patients were accrued at the next lower dose 
level. The RD was defined as the dose at which two or 
fewer of six patients experienced a DLT. If two or fewer 
of the six patients in dose level 1 experienced a DLT, the 
RD was determined to be level 1 (DTX 70 mg/m2, CDDP 
70 mg/m2 and 5-FU 750 mg/m2).
The dose was modified for each patient based on hema-
tologic or non-hematologic toxicity. DLT was defined 
as any of the following adverse events occurring within 
28 days after completion of the protocol treatment: (1) 
febrile neutropenia lasting >4 days; (2) grade 4 thrombocy-
topenia (<0.25 × 109/l); (3) grade 3 or 4 non-hematologic 
toxic effects, except grade 3 alopecia, anorexia, nausea, 
vomiting, constipation, stomatitis, esophagitis or infection 
due to stomatitis; (4) discontinuation of treatment due to an 
adverse event; or (5) treatment-related death.
In the subsequent phase II part, the enrolled patients 
were treated with the RD of induction chemotherapy fol-
lowed by concurrent chemoradiotherapy as above.
Study assessment
Pretreatment evaluation included a medical history; physi-
cal examination; complete blood cell count and serum 
chemistry tests; esophagogastroduodenoscopy; and cervi-
cal, chest and abdominal CT scans. Endoscopic ultrasound, 
bronchoscopy and cervical ultrasound were optional. Adja-
cent organs were considered to be involved if the tumor 
extended into the lumen or caused a deformity of the air-
way in the trachea or tracheobronchial tree, and if the 
tumor was attached to the organ at a contact angle ≥90° in 
the thoracic aorta as observed on the CT scan. T3 or lesser 
extent of disease was determined by endoscopic ultrasound. 
Lymph nodes were considered positive if they were ≥1 cm 
in diameter on any image. These evaluations for staging 
were reviewed, and cases were judged as potentially incur-
able with surgery by diagnostic radiologists as well as sur-
geons and medical oncologists at each institution.
All adverse events experienced during the study were 
recorded and graded according to the National Cancer 
Institute Common Terminology Criteria for Adverse Events 
(CTCAE version 3.0). Late toxicity was graded according 
to the RTOG/EORTC Late Radiation Morbidity Scoring 
Scheme. Late toxicity was defined as toxicity occurring 
more than 31 days after treatment completion. Close fol-
low-up using both endoscopy and CT was mandatory in the 
third week of every induction chemotherapy administra-
tion. If disease progression or new metastasis was detected, 
the subsequent cycle of induction chemotherapy was dis-
continued and a shift to chemoradiation was mandated. A 
history and physical examination, serum chemistry pro-
file, cervical–chest–abdominal CT scan and esophagogas-
troduodenoscopy were performed in the fourth week after 
the completion of all protocol therapy. The following were 
performed every 3 months for 1 year and every 6 months 
thereafter until disease progression: physical examina-
tion, toxicity assessment, complete blood cell count, serum 
chemistry profile, cervical–chest–abdominal CT scan and 
esophagogastroduodenoscopy. Patterns of failure were 
defined as the first site of failure. Local/regional failure 
included the primary tumor and regional lymph nodes. Dis-
tant failure included any site beyond the primary tumor and 
regional lymph nodes.
Endpoints and statistical analysis
Once the RD of induction chemotherapy was determined 
in the first phase of the study, patient accrual continued 
for the phase II study, the main objective of which was 
to determine the objective response activity of this strat-
egy. The primary endpoint was complete response (CR) 
rate evaluated according to the Response Evaluation Cri-
teria in Solid Tumors (RECIST) criteria v1.0 and endo-
scopic assessment for the primary tumor. Primary tumor 
response was evaluated using endoscopy in accordance 
with the modified criteria of the tenth edition of Guide-
lines for the Diagnosis and Treatment of Carcinoma of the 
Esophagus, issued by the Japanese Society for Esopha-
geal Diseases [16]. For the primary site, clinical CR was 
defined as disappearance of the primary tumor, ulceration 
and erosion as confirmed by endoscopic examination and 
negative biopsy results. A CR of lymph node metastasis 
was defined as the disappearance of all visible lymph 
node metastases on CT imaging. A CR was defined as a 
clinical CR of the primary tumor and CR of lymph node 
metastases. An evaluation of CR had to be confirmed by 
reassessment on endoscopy and CT 4 or more weeks later. 
Secondary endpoints included progression-free survival 
(PFS), overall survival (OS), response rate of induction 
chemotherapy, completion rate of protocol treatment and 
safety. We set the threshold objective CR rate at 30 % and 
the expected objective CR rate at 50 % on the basis of 
the results of previous studies [3, 8]. Given a one-sided 
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α of 0.1 and statistical power of 80 %, a minimum of 27 
patients was required.
The survival curve was estimated using the Kaplan–
Meier method. Safety and efficacy analyses were both con-
ducted on an intention-to-treat (ITT) population, defined as 
all patients enrolled in the study who received at least one 
dose of induction chemotherapy. The PFS was defined as 
the time from the date of first administration of induction 
chemotherapy to the first documentation of disease pro-
gression, subsequent therapy or death. OS was determined 
from the date of first administration of induction chemo-
therapy to the date of death or last confirmation of survival. 
Statistical data were obtained using the SPSS software 
package (SPSS 22.0 Inc., Chicago, IL).
This trial was registered with University Hospital Medi-
cal Information Network (No. UMIN000003370).
Results
Patient characteristics
Thirty-three patients with histologically proven squamous 
cell carcinoma were enrolled from August 2009 to Novem-
ber 2011. The 33 patients are characterized in Table 1. 
Baseline nutritional statuses were total protein median 
7.0 g/dl (range 5.9–8.0) and serum albumin level median 
4.0 g/dl (range 2.8–4.8). There were 16 patients (48 %) 
with T4 M0 disease, 13 (39 %) with non-T4 M1 LYM and 
4 (12 %) with T4 M1 LYM. The site of clinical involve-
ment in the 20 cases of T4 disease was the trachea in 15, 
trachea and thoracic aorta in 2 and thoracic aorta, pericar-
dium and stomach in 1 case each.
Among the six patients who were registered to phase I, 
all patients were treated at the RD (level 1: DTX 70 mg/
m2, CDDP 70 mg/m2 and 5-FU 750 mg/m2). Twenty-seven 
other patients were entered into phase II to further evalu-
ate the tolerability and toxicity of the study regimen. All 33 
patients were evaluated for toxicity and efficacy.
Phase 1
The first six patients were enrolled at dose level 1 (DTX 
70 mg/m2, CDDP 70 mg/m2 and 5-FU 750 mg/m2). No 
DLTs were observed, and hence, the RD was determined to 
be DTX 70 mg/m2, CDDP 70 mg/m2 and 5-FU 750 mg/m2. 
All six patients completed the three courses of induction 
chemotherapy, and five patients received subsequent chem-
oradiation without cessation. The sixth patient required the 
temporary cessation of radiation therapy due to infection 
for 5 days, but completed all subsequent irradiation.
Toxicity
The worst toxicity throughout the treatment period is listed 
in Table 2. During the induction chemotherapy phase, grade 
3 or 4 neutropenia and febrile neutropenia (FN) occurred 
in 72 and 6 % of patients, respectively. Of these patients, 
12 patients were administered G-CSF for FN or grade 4 
neutropenia. One patient with grade 4 FN developed pneu-
monia with shock, but recovered following treatment with 
G-CSF and antibiotics. Another patient with grade 4 FN, 
whose primary tumor involved the trachea at initial diagno-
sis, developed treatment-related perforation of the esopha-
geal wall, leading to an esophagotracheal fistula after the 
first cycle of induction chemotherapy.
During the chemoradiation phase, grade 3 or 4 neutrope-
nia and FN occurred in 18 and 3 % of patients, respectively. 
Of these, one patient required G-CSF for 2 days starting 
from the 20th day of irradiation. One patient with T4 dis-
ease involving the trachea at initial diagnosis developed 
treatment-related perforation of the esophageal wall, and 
an esophagomediastinal fistula occurred on the 16th day 
from the start of irradiation. No treatment-related death was 
observed during the protocol treatment.
Six patients experienced late toxicities related to treat-
ment, two with grade 2 esophageal stricture, two with 
grade 1 or 2 peripheral sensory neuropathy, one with grade 
1 pleural effusion and one with grade 1 radiation pneumo-
nitis. No patient experienced grade 3 or higher late toxicity.
Table 1  Patient characteristics (n = 33)
ECOG Eastern Cooperative Oncology Group, PS performance status
Variable n (%)
Age Median 61
Range 30–69
Sex Male 29 (88)
Female 4 (12)
ECOG PS 0 19 (58)
1 14 (42)
Tumor location Upper thorax 18 (55)
Middle thorax 13 (39)
Lower thorax 2 (6)
Clinical TNM and stage
 III T4N1M0 16 (48)
 IVA T2N0M1a 1 (3)
T2N1M1a 1 (3)
T3N1M1a 8
T4N1M1a 3
 IVB T3N1M1b 3
T4N1M1b 1 (3)
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Table 2  Adverse events during 
the treatment period (n = 33) Grade
1 2 3 4 All, % 3/4, %
Adverse events during induction chemotherapy
Hematologic
 Leukopenia 5 15 11 2 100 39
 Neutropenia 0 9 12 12 100 72
 Anemia 22 11 0 0 100 0
 Thrombocytopenia 22 11 0 0 100 0
Non-hematologic
 Creatinine increased 7 0 0 0 21 0
 Elevation of AST 14 0 0 0 42 0
 Elevation of ALT 10 9 1 0 30 3
 Febrile neutropenia – – 1 1 6 6
 Hyperbilirubinemia 3 1 0 0 12 0
 Hyponatremia (≥G3) – – 1 1 6 6
 Alopecia 14 6 0 0 60 0
 Anorexia 10 13 6 0 87 18
 Constipation 8 6 0 0 42 0
 Diarrhea 9 3 0 0 38 0
 Dysphagia 7 6 4 0 51 12
 Edema 2 0 1 0 9 3
 Fever 2 0 1 0 9 3
 Fistula GI-esophagus 0 0 1 0 3 3
 Infection with normal ANC 0 0 1 1 6 6
 Nausea 13 7 3 0 69 9
 Rash 3 0 0 0 9 0
 Stomatitis 11 6 1 0 54 3
 Vomiting 3 2 0 0 15 0
Adverse events during chemoradiation
Hematologic
 Leukopenia 5 15 8 0 85 24
 Neutropenia 11 10 6 0 82 18
 Anemia 6 22 1 0 88 3
 Thrombocytopenia 9 2 0 0 33 0
Non-hematologic
 Creatinine increased 8 1 0 0 27 0
 Elevation of AST 5 0 0 0 15 0
 Elevation of ALT 0 7 0 0 21 0
 Febrile neutropenia – – 1 0 3 3
 Alopecia 14 8 0 0 67 0
 Anorexia 12 6 4 0 67 12
 Constipation 9 0 0 0 27 0
 Diarrhea 4 0 0 0 12 0
 Dysphagia 8 8 5 0 64 15
 Edema 1 1 0 0 6 0
 Esophagitis (≥G3) – – 4 0 – 12
 Fever 2 0 0 0 6 0
 Fistula GI-esophagus 0 0 1 0 3 3
 Infection with normal ANC 1 0 1 0 6 3
 Nausea 12 3 3 0 55 9
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Dose intensity
During the induction chemotherapy phase, the median 
percentage of relative dose intensity (RDI) delivered was 
83.6 % (range 33.0–100) for docetaxel, 81.5 % (range 
33.0–100) for cisplatin and 84.1 % (range 33.2–100) for 
fluorouracil. The average RDI of induction chemotherapy 
was 83.0 %. Four of 33 patients (12 %) discontinued 
induction chemotherapy due to toxicity; of these, 3 dis-
continued after the first cycle of induction DCF, one each 
due to grade 4 hyponatremia, grade 4 febrile neutrope-
nia and esophagotracheal fistula. One patient discontin-
ued induction DCF after the second cycle due to grade 
4 sepsis. During the chemoradiation phase, the median 
dose intensity delivery was 85.8 % (range 30.0–100) for 
cisplatin and 94.1 % (range 49.9–100) for fluorouracil. 
The average RDI of chemotherapy was 90.0 %. Patients 
required dose reduction mainly due to bone marrow sup-
pression, renal toxicity (creatinine clearance < 60 mL/
min) or stomatitis. The completion rate of protocol treat-
ment was 87.8 %.
Response to treatment
Response to induction chemotherapy and chemoradio-
therapy is summarized in Table 3. Two of the 33 patients 
had CR after induction chemotherapy, and thirteen 
patients (39.4 %, 95 % CI 21.8–57.0 %) had CR after 
chemoradiation.
Survival and patterns of failure
With a median follow-up period of 41 months (range 
24–49 months), median survival was 26.0 months (95 % 
CI 11.8–40.2), and 1- and 3-year survival rates were 
78.8 % (95 % CI 60.6–89.3) and 40.4 % (95 % CI 23.3–
56.9), respectively (Fig. 1). The median time to progres-
sion was 12.2 months (95 % CI 8.2–16.2), and 1- and 
3-year progression-free survival rates were 51.5 % (95 % 
CI 33.5–66.9) and 27.3 % (95 % CI 13.6–42.9), respec-
tively (Fig. 2). No significant difference (p = 0.911) was 
seen in survival benefit between T4 and non-T4 groups, 
with an overall survival time of 26.0 versus 25.6 months, 
respectively.
Among all 33 patients, 21 (64 %) received post-protocol 
treatment. Eight patients underwent salvage surgery, with 
five cases of curative resection. Three patients underwent 
salvage endoscopic resection, with two cases of patho-
logical complete resection. Three cases went off-protocol 
due to adverse events during induction chemotherapy and 
received definitive chemoradiotherapy (two with CF-RT 
and one with 5-FU/nedaplatin-RT), with one case of com-
plete response. One patient received definitive chemoradio-
therapy with a CF regimen due to recurrence out of a prior 
radiation field. Nine patients received palliative chemother-
apy for progression.
Table 2  continued Grade
1 2 3 4 All, % 3/4, %
 Neuropathy sensory 2 0 0 0 6 0
 Stomatitis 4 0 0 0 12 0
 Vomiting 3 1 0 0 12 0
Table 3  Response rate to treatment (n = 33)
CI confidence interval, CRT chemoradiation
Variable n % (95% CI)
Response after induction chemotherapy
 Overall 20 60.6 (43.7–77.5)
 Complete response 2 6.1 (0–14.7)
 Partial response 18 54.5 (36.6–72.5)
Response after CRT
 Overall 24 72.7 (55.8–84.9)
 Complete response 13 39.4 (24.7–56.3)
 Partial response 11 33.3 (19.8–50.4)
Fig. 1  Kaplan–Meier estimates of overall survival (n = 33)
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Patterns of first failure are shown in Table 4. All failures 
occurred within 1 year (range 6.1–8.0 months) after confir-
mation of clinical CR.
Discussion
In this multicenter prospective trial of induction chemo-
therapy followed by concurrent CRT, induction DCF 
showed substantial activity in patients with unresectable 
locally advanced ESCC. Previous studies of concurrent 
chemoradiotherapy with cisplatin and 5-FU in patients with 
ESCC with T4 tumors and/or M1 LYM showed a clinical 
complete response rate of 15–33 % with a median PFS of 
6 months and a 3-year overall survival rate of 23–26 % [3, 
8, 9]. Our present study did not achieve the expected CR 
rate (39.4 %), but did demonstrate promising efficacy, with 
a median PFS of 12 months and a 3-year survival rate of 
40.4 %.
The reason for not achieving the expected CR rate is 
unclear. The recent randomized phase 3 trials with induc-
tion chemotherapy for locally advanced head and neck 
squamous cell carcinoma showed survival benefits for DCF 
compared to CF, but the percentages of patients with a 
complete response and overall response did not statistically 
differ [12]. Patterns of failure in our present study showed 
that the distant recurrence rate was quite low (9 %). These 
might mean that this induction chemotherapy contributes 
to survival benefit by controlling minor metastases, but 
does not contribute to clinical response. The prolongation 
of PFS was clearly aided by the induction chemotherapy. 
Furthermore, post-protocol treatment, such as salvage sur-
gery/endoscopic resection and palliative chemotherapy, 
might also have contributed to the regimen’s survival bene-
fit. Only esophagectomy has curative potential, but salvage 
surgery is associated with high morbidity rates [17–19]. 
The participating centers in our present study are regarded 
as highly specialized, and complications of salvage surgery 
might therefore have been minimized. Salvage endoscopic 
resection has curative intent for patients with locoregional 
failure after definitive CRT for ESCC [20]. Moreover, sal-
vage chemotherapy with taxanes has shown a clinical ben-
efit for ESCC in patients who previously received plati-
num-based chemotherapy [21, 22]. While Ohtsu et al. [8] 
reported that survival rate with T4 disease was inferior to 
that with non-T4 disease, we saw no significant difference 
in response rate or survival benefit between our T4 and 
non-T4 groups, with an overall survival time of 26.0 versus 
25.6 months, respectively.
Of the 13 patients who had no response after induction 
chemotherapy (clinical SD or PD), 2 achieved clinical CR 
and 4 achieved clinical PR after subsequent definitive CRT. 
A shift in strategy to definitive CRT might therefore be 
effective for non-responders to induction chemotherapy.
Although induction DCF induced severe neutropenia, 
as expected, febrile neutropenia occurred in only 6 % due 
to prophylactic use of ciprofloxacin. The risk of perfora-
tion of the esophageal wall related to definitive CRT has 
been highlighted in patients with T4 disease. Previous stud-
ies reported a frequency of perforation of the esophageal 
wall of 14–23 % in patients with T4 disease who received 
CRT [8, 9]. To reduce the risk of perforation, we decided 
to use induction chemotherapy before CRT, with the aim 
of decreasing tumor volume before encountering severe 
esophagitis. Treatment-related perforation of the esopha-
geal wall occurred in only one patient during induction 
chemotherapy (3 %) and in a second patient during CRT 
(3 %). This incidence is lower than in the previous study [8, 
9], suggesting that this strategy was effective, albeit with 
room for improvement. We did not mandate bronchoscopy 
to evaluate the degree of invasion of the trachea before 
treatment; doing so in T4 tracheal lesions before treatment 
will allow the prediction of perforation risk.
Induction with DCF followed by concurrent CRT using 
carboplatin was previously reported to have a CR rate of 
Fig. 2  Kaplan–Meier estimates of progression-free survival (n = 33)
Table 4  Patterns of failure (n = 33)
n %
Alive/no failure 8 24
Any failure 25 76
 Persistent local disease 18 55
 Local recurrence 1 3
 Regional lymph node recurrence 3 9
 Distant recurrence 3 9
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16 % and median overall survival of 10.8 months [15]. Fur-
ther, Higuchi et al. [23] reported that definitive CRT with 
DCF (DCF-R) for locally advanced ESCC had a high clin-
ical CR rate (52.4 %) as well as prolonged PFS (median 
11.1 months) and OS (MST 29.0 months). Although these 
survival data were equivalent to those of our present study, 
DCF-R was associated with a relatively high incidence of 
FN (grade 3 or more, 38.1 %) and late toxic effects, namely 
grade 3 or more pericardial effusion (2.6 %), esophagus-
related toxicities (7.7 %) and cardiovascular toxicities 
(2.6 %). Accordingly, the use of induction chemotherapy 
followed by concurrent CRT or definitive DCF-R using 
three cytotoxic drugs for T4 and/or M1 LYM is still under 
discussion.
Several limitations of the study warrant mention. The 
total dose of irradiation for locally advanced ESCC is 
still not standardized. The Intergroup 0123 study found 
no improvement in survival or locoregional control when 
comparing a radiotherapy dose of 64.8 Gy with 50.4 Gy 
[24]. On this basis, the standard radiation dose for defini-
tive CRT is now 50.0–50.4 Gy in the USA. In Japan, defin-
itive chemoradiotherapy with ≥60 Gy has been employed 
to treat locally advanced ESCC, especially for T4 and/or 
M1 LYM [3, 8, 25]. Irradiation in our present study con-
sisted of 60 Gy with a daily dose of 2 Gy. However, high-
dose irradiation might increase the risk of perforation of 
the esophageal wall in the chemoradiation phase. Although 
the study included the efficacy and safety of induction 
DCF followed by CRT for patients with locally unresect-
able ESCC, it was conducted at expert centers in Japan. 
Thus, a conclusive answer to the optimum strategy for 
locally unresectable ESCC will require prospective ran-
domized controlled trials at multiple institutions with a 
larger number of patients.
In conclusion, this study showed that induction chem-
otherapy with DCF followed by CRT was tolerable, 
and might feasible in patients with unresectable locally 
advanced ESCC.
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